Phase 2 study to investigate the safety and efficacy of ABBV-105 administered alone or in combination with upadacitinib (combination ABBV-599) with a background treatment with conventional synthetic DMARDs in subjects with active rheumatoid arthritis with insufficient response or intolerance to FRAME biological
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ABBVIE SPAIN SLU
- Phase: II
- Execution start: 30/04/2019
- End of execution: 30/01/2020
- IP: RAFAEL CALIZ CALIZ